Literature DB >> 12614093

Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies.

Christopher M Clark1, Jason H T Karlawish.   

Abstract

Alzheimer disease is a complex neurodegenerative dementing illness. It has become a major public health problem because of its increasing prevalence, long duration, high cost of care, and lack of disease-modifying therapy. Over the past few years, however, remarkable advances have taken place in understanding both the genetic and molecular biology associated with the intracellular processing of amyloid and tau and the changes leading to the pathologic formation of extracellular amyloid plaques and the intraneuronal aggregation of hyperphosphorylated tau into neurofibrillary tangles. The identification of disease-causing autosomal dominant mutations as well as gene polymorphisms that alter the risk for pathology indicate that Alzheimer disease is a genetically complex disorder. This progress in our understanding of the molecular pathology has set the stage for clinically meaningful advances in diagnosis and treatment. Emerging diagnostic methods that are based on biochemical and imaging biomarkers of disease-specific pathology hold the potential for accurately diagnosing Alzheimer disease at the earliest stage of the illness--the time when disease-modifying treatment will be most effective. Currently available cholinesterase inhibition therapy targets the cognitive symptoms. However, the goal of new therapies under development is halting the pathologic cascade and potentially reversing the course of the disease. If these new therapies are successful, they will represent a remarkable medical advance for patients and the families who care for them.

Entities:  

Mesh:

Year:  2003        PMID: 12614093     DOI: 10.7326/0003-4819-138-5-200303040-00010

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  27 in total

1.  Investigation of the noncovalent interactions between anti-amyloid agents and amyloid beta peptides by ESI-MS.

Authors:  Eric Martineau; Janna M de Guzman; Lioudmila Rodionova; Xianqi Kong; Paul M Mayer; Ahmed M Aman
Journal:  J Am Soc Mass Spectrom       Date:  2010-05-31       Impact factor: 3.109

2.  Pre-aggregated Aβ1-42 peptide increases tau aggregation and hyperphosphorylation after short-term application.

Authors:  Sabine Ott; Andreas Wolfram Henkel; Maria Kerstin Henkel; Zoran B Redzic; Johannes Kornhuber; Jens Wiltfang
Journal:  Mol Cell Biochem       Date:  2010-11-27       Impact factor: 3.396

Review 3.  Galantamine extended release in Alzheimer's disease: profile report.

Authors:  Dean M Robinson; Greg L Plosker
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

4.  Discovery and structure activity relationship of small molecule inhibitors of toxic β-amyloid-42 fibril formation.

Authors:  Heiko Kroth; Annalisa Ansaloni; Yvan Varisco; Asad Jan; Nampally Sreenivasachary; Nasrollah Rezaei-Ghaleh; Valérie Giriens; Sophie Lohmann; María Pilar López-Deber; Oskar Adolfsson; Maria Pihlgren; Paolo Paganetti; Wolfgang Froestl; Luitgard Nagel-Steger; Dieter Willbold; Thomas Schrader; Markus Zweckstetter; Andrea Pfeifer; Hilal A Lashuel; Andreas Muhs
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

5.  Psychotic symptoms in the elderly.

Authors:  Rebecca W Brendel; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

6.  Deliberative assessment of surrogate consent in dementia research.

Authors:  Scott Y H Kim; Rebecca A Uhlmann; Paul S Appelbaum; David S Knopman; H Myra Kim; Laura Damschroder; Elizabeth Beattie; Laura Struble; Raymond De Vries
Journal:  Alzheimers Dement       Date:  2010-02-26       Impact factor: 21.566

Review 7.  Biomarkers in Alzheimer's disease: past, present and future.

Authors:  Katarzyna Gustaw-Rothenberg; Alan Lerner; David J Bonda; Hyoung-gon Lee; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

8.  Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors.

Authors:  Sawsan Abuhamdah; Maha Habash; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2013-12-12       Impact factor: 3.686

9.  Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects.

Authors:  Xue Hua; Suh Lee; Igor Yanovsky; Alex D Leow; Yi-Yu Chou; April J Ho; Boris Gutman; Arthur W Toga; Clifford R Jack; Matt A Bernstein; Eric M Reiman; Danielle J Harvey; John Kornak; Norbert Schuff; Gene E Alexander; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2009-07-14       Impact factor: 6.556

10.  Comparison of persistence rates of acetylcholine-esterase inhibitors in a state Medicaid program.

Authors:  Susan M Abughosh; Stephen J Kogut
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.